Benralizumab is effective in reducing asthma exacerbations: Results from the ZEPHYR 2 study

被引：0
|
作者：
Maselli, Diego J.
Carstens, Donna
Yang, Danni
Mu, Fan
Young, Joshua
Cook, Erin E.
Betts, Keith A.
Chung, Yen
机构：
来源：
ALLERGY AND ASTHMA PROCEEDINGS | 2022年 / 43卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：565 / 565
页数：1
相关论文
共 50 条
  • [41] Benralizumab-induced asthma remission: evidence from the real-world imPROve study
    Lommatzsch, M.
    Korn, S.
    Grund, T.
    Emmanuel, B.
    Shavit, A.
    Plate, T.
    Saathoff, M.
    Watz, H.
    ALLERGOLOGIE, 2022, 45 (08) : 615 - 615
  • [42] Benralizumab efficacy for severe, eosinophilic asthma with a diagnosis of nasal polyposis: Results from the phase IIIb ANDHI trial
    Canonica, G. W.
    Harrison, T. W.
    Chanez, P.
    Menzella, F.
    Louis, R.
    Cosio, B. G.
    Lugogo, N. L.
    Mohan, A.
    Burden, A.
    Mcdermott, L.
    Garcia Gil, E.
    Zangrilli, J. G.
    ALLERGY, 2020, 75 : 114 - 114
  • [43] Benralizumab-induced asthma remission: evidence from the real- world imPROve study
    Lommatzsch, M.
    Korn, S.
    Grund, T.
    Emmanuel, B.
    Shavit, A.
    Plate, T.
    Saathoff, M.
    Watz, H.
    PNEUMOLOGIE, 2023, 77 : S76 - S77
  • [44] ROLE OF VIRAL-INFECTIONS IN EXACERBATIONS OF ASTHMA - STUDY SUPPORTS RESULTS OF AUDIT BY GENERAL-PRACTITIONERS IN ASTHMA GROUP
    NEVILLE, R
    HOSKINS, G
    SMITH, B
    BRITISH MEDICAL JOURNAL, 1995, 311 (7005): : 629 - 629
  • [45] Early response to benralizumab in Canadian patients with severe eosinophilic asthma: Interim results from a prospective observational cohort
    Noorduyn, Stephen G.
    Kayaniyil, Sheena
    Lancaster, Brett
    Dorscheid, Delbert
    Tourin, Olga
    Walker, Brandie
    Thawer, Amin
    Ramesh, Warren
    Khan, Irfan
    Kim, Harold
    Sussman, Gordon
    Mbuagbaw, Lawrence
    Penz, Erika
    CANADIAN JOURNAL OF RESPIRATORY CRITICAL CARE AND SLEEP MEDICINE, 2024, 8 (03) : 99 - 107
  • [46] Characteristics of Asthma Exacerbations That Required Hospitalization in Patients with Severe, Uncontrolled Asthma Receiving Tezepelumab Compared with Placebo: Results from the Phase 3 NAVIGATOR Study
    Ambrose, C. S.
    Cook, B.
    Roseti, S. L.
    Gelhorn, H.
    Cutts, K.
    Lindsley, A. W.
    Colice, G.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [47] Influence of Baseline Total IgE and History of Previous Omalizumab Use on the Impact of Mepolizumab in Reducing Rate of Severe Asthma Exacerbations: Results From the Real-World REALITI-A Study
    Lee, Jason
    Pollard, Stephen
    Liu, Mark
    Schleich, Florence
    Pelaia, Girolamo
    Almonacid, Carlos
    Heaney, Liam
    Chaudhuri, Rekha
    Alfonso-Cristancho, Rafael
    Jakes, Rupert
    Price, Robert
    Maxwell, Aoife
    Howarth, Peter
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB191 - AB191
  • [48] Impact of mepolizumab on exacerbations in severe asthma: Results from a US insurance claims data base
    Ortega, Hector
    Hahn, Beth
    Bogart, Michael
    Bell, Christopher F.
    Bancroft, Tim
    Chastek, Benjamin
    Llanos, Jean-Pierre
    ALLERGY AND ASTHMA PROCEEDINGS, 2020, 41 (05) : 341 - 347
  • [49] High Burden of Exacerbations of Severe Asthma: Results from a Real-World Study of Patients Treated by Subspecialists in the United States
    Carr, Warner
    Lugogo, Njira
    Moore, Wendy
    Panettieri, Reynold
    Soong, Weily
    Trudo, Frank
    Ambrose, Chris
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB109 - AB109
  • [50] Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: Results from the Phase 3 NAVIGATOR Study
    Hoyte, Flavia
    Martin, Neil
    Kmita, Kamil
    Roseti, Stephanie
    Llanos-Ackert, Jean-Pierre
    Lindsley, Andrew
    Colice, Gene
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (02) : AB63 - AB63
12345